Boralex’s removal from the TSX narrows Canada’s listed clean-energy universe and highlights institutional demand for ren…

Mobix Labs’ proposed Special Project Delivery acquisition would shift MOBX toward rare earths, critical minerals, energy…

Goldman Sachs’ agreement to acquire NEOS for up to $2.25 billion expands its asset-management reach into options-overlay…

Tarsus is acquiring Alkeus and its Phase 3 Stargardt disease candidate ALK-001, while Harrow’s TYRVAYA deal highlights o…

SpaceX’s first post-IPO earnings report could set its early valuation narrative as traders weigh a bullish analyst view …

FCPT's acquisition of a Burger King property signals growth in net-lease investments, appealing to income-focused invest…

Freenome's IPO marks a significant step in blood-based cancer detection, reshaping the landscape for biotech investors.

Palomino Laboratories is set to acquire Vega Links, marking a strategic move into the AI interconnect space.

SpaceX shares fell below the $135 IPO price for the first time, raising concerns among traders about future performance.

NextCure's merger with Avere Therapeutics could position NXTC for growth in the public markets.

General Fusion is on track to become the first publicly traded fusion company, a significant milestone for the energy se…

Lime's $1.7 billion IPO highlights a resurgence in market enthusiasm for new public offerings.